Canadian Treat and Extend Analysis Trial With Ranibizumab
NCT02103738
·
clinicaltrials.gov ↗
COMPLETED
Status
505
Enrollment
INDUSTRY
Sponsor class
Conditions
wetAMD
Interventions
OTHER:
0.5 mg Ranibizumab intravitreal injections
Sponsor
Novartis Pharmaceuticals